ITC Begins Section 337 Investigation on Antirheumatic Drug
The International Trade Commission officially opened an investigation into alleged misappropriation of trade secrets relating to the manufacture of the antirheumatic drug Adalimumab. The investigation (ITC Inv. No. 337-TA-1296) is based on a complaint filed by AbbVie Dec. 17 (see…
Sign up for a free preview to unlock the rest of this article
Export Compliance Daily combines U.S. export control news, foreign border import regulation and policy developments into a single daily information service that reliably informs its trade professional readers about important current issues affecting their operations.
2112230048), alleging that Alvotech, Teva Pharmaceutical Industries and Ivers-Lee engaged in "a scheme to improperly recruit employees with knowledge of AbbVie's manufacturing process for Adalimumab," in an attempt to market a biosimilar called AVT02. AbbVie asked the ITC to issue a limited exclusion order and cease and desist orders banning importation and sale of covered goods by Alvotech, Teva and Ivers-Lee and their affiliates.